Elucida Oncology develops targeted C'Dot Drug Conjugates (CDCs) for patients with primary solid tumor and metastatic cancer.
Elucida Oncology has raised $22.9M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in June 2023.
Elucida Oncology's investors include Lynx Capital.
Elucida Oncology is headquartered in Monmouth Junction, United States.
Elucida Oncology develops targeted C'Dot Drug Conjugates (CDCs) for patients with primary solid tumor and metastatic cancer.
Elucida Oncology is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Elucida Oncology — Funding & Investors." VCBacked, June 15, 2023, https://www.vcbacked.co/company/elucida-oncology. Accessed August 6, 2026.
VCBacked. (2023). Elucida Oncology — Funding & Investors. Retrieved August 6, 2026, from https://www.vcbacked.co/company/elucida-oncology
{{cite web |title=Elucida Oncology — Funding & Investors |url=https://www.vcbacked.co/company/elucida-oncology |website=VCBacked |access-date=August 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated